Functional orthogonality of WRN inhibitor resistance enables alternating therapy and mutation-tolerant inhibitor design in MSI-H cancers
Guizhen Zhou, Dan Teng, Dan Wang, Miao Pang, Zisheng Fan, Yuyan Tao, Shuai Chen, Xiaomin Yang, M W Huang, Panpan Shao, Yun Liu, Rongrong Cui, Zhiyin Xie, Yi Zhou, Zhiming Ge, , Mingyue Zheng
This study shows that resistance to different WRN inhibitors in MSI-H cancers creates orthogonal vulnerabilities, enabling alternating therapy and mutation-tolerant inhibitor design.
bioRxiv · Jun 12, 2026 · PreprintCancer Biology